Attacking migraine headache from beginning to end

Editorial

M A Moskowitz et al. Neurology. 1997 Nov.

. 1997 Nov;49(5):1193-5.

doi: 10.1212/wnl.49.5.1193.

No abstract available

Comment on

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL. Rapoport AM, et al. Neurology. 1997 Nov;49(5):1210-8. doi: 10.1212/wnl.49.5.1210. Neurology. 1997. PMID: 9371896 Clinical Trial.
Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group.
Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Solomon GD, et al. Neurology. 1997 Nov;49(5):1219-25. doi: 10.1212/wnl.49.5.1219. Neurology. 1997. PMID: 9371897 Clinical Trial.
Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies.
Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Ryan R, et al. Neurology. 1997 Nov;49(5):1225-30. doi: 10.1212/wnl.49.5.1225. Neurology. 1997. PMID: 9371898 Clinical Trial.
A new locus for hemiplegic migraine maps to chromosome 1q31.
Gardner K, Barmada MM, Ptacek LJ, Hoffman EP. Gardner K, et al. Neurology. 1997 Nov;49(5):1231-8. doi: 10.1212/wnl.49.5.1231. Neurology. 1997. PMID: 9371899